STEVEN ISAACMAN, PH.D.
ANDREW MAHON, PH.D.
Chief Scientific Officer, Medicinal Chemistry | Dr. Mahon received his PhD in Chemistry at Macquarie University, Sydney, Australia, before taking up post-doctoral positions at the California Institute of Technology and New York University. He has gained an expert knowledge of small molecule and peptide synthesis, NMR spectroscopy and protein-protein interaction inhibitor design.
MICHAEL ISAACMAN, PH.D.
Director of Research, Medicinal Chemistry | Dr. Isaacman received his Ph.D. from the University of California, Santa Barbara where his research focused on the design and synthesis of silicone-based amphiphilic block co-polymers for drug delivery and personal care. An expert in skin cancer prevention, Dr. Isaacman leads a National Cancer Institute funded project that aims to develop long-wear sunscreens that are more substantive with human skin. Michael has published in the fields of skin care, natural product synthesis, pollutant sensors, and polymer chemistry.
Head of Clinical Operations | Scott Spector is an accomplished clinical development executive with 20 years of pharmaceutical product development experience. He is currently President of Spector Consulting, LLC. Scott is focused on providing strategy-driven product development support and outcomes that enable small to mid-sized biotech companies to accelerate development timelines, reduce development costs and mitigate risk. Prior to creating Spector Consulting, Scott was the European President of Siro Clinpharm, an emerging market CRO with a strong emphasis on the CEE and India. Scott’s career in clinical development started at Quintiles Transnational, where he was instrumental in leading the growth of the company’s European operations. Scott served as the President of Quintiles France and Spain and was also the global operations head of the CNS and Anti-Infectives business units. Following a 10-year career at Quintiles, Scott became President of CAC Oncology, an early pioneer in oncology contract research services and drug development consulting. Upon the sale of CAC Oncology to AAIPharma, Scott became President of a newly created entity called AAI Oncology. Scott holds a BS/BA in Finance from Boston University and a Professional Certificate in Genetics and Genomics from Stanford University.
JAMES CANARY, PH.D.
Scientific Advisory Board Member & Consultant | Dr. James Canary is a professor of chemistry at New York University and leads a research group that uses molecular modeling and organic synthesis to engineer materials with designed properties at the interface between biomedical chemistry and nanoscience. Efforts in the group include the application of stereochemistry to the development of materials for molecular electronics and nanotechnology, drug development projects involving organic catalysts and related compounds, and the design and fabrication of molecular imaging agents for cancer.
INFO@PHDBIOSCIENCES | 646.801.3872 | 14 EAST 4TH STREET, SUITE 811, NEW YORK, NY 10012 ©2016 PHDBIOSCIENCES